vTv Therapeutics (NASDAQ:VTVT) Earns “Buy” Rating from BTIG Research

vTv Therapeutics (NASDAQ:VTVT)‘s stock had its “buy” rating reaffirmed by BTIG Research in a note issued to investors on Wednesday, Benzinga reports. They presently have a $57.00 price objective on the biotechnology company’s stock. BTIG Research’s target price suggests a potential upside of 106.60% from the company’s previous close.

VTVT has been the topic of several other reports. Weiss Ratings lowered vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Lifesci Capital upgraded vTv Therapeutics to a “strong-buy” rating in a report on Wednesday, September 2nd. Rodman & Renshaw initiated coverage on vTv Therapeutics in a research report on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price objective for the company. Finally, Wall Street Zen raised vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $55.83.

vTv Therapeutics Stock Performance

NASDAQ:VTVT traded up $0.07 during trading hours on Wednesday, hitting $27.59. The stock had a trading volume of 22,240 shares, compared to its average volume of 53,367. The business’s 50 day moving average is $31.76 and its 200-day moving average is $33.48. The company has a market cap of $108.68 million, a price-to-earnings ratio of -26.03 and a beta of 0.21. vTv Therapeutics has a one year low of $19.50 and a one year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). On average, sell-side analysts anticipate that vTv Therapeutics will post -2.35 EPS for the current fiscal year.

About vTv Therapeutics

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.